GlassScriptPhysician profile
Carmelina Dimatteo
NPI 1437286689
$10,935.02
in general payments reported to CMS, 2019-2025
38 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,864 · 2022: $2,197 · 2023: $3,111 · 2024: $2,344 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,795 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,794.57 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,424.98 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,226.17 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $868.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $842.18 | 2021-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $711.58 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $597.84 | 2021-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $541.33 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $490.27 | 2021-2024 | Verquvo, Steglatro |
| Amgen INC. | $384.76 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $342.59 | 2021-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $285.96 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $275.39 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $270.00 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $198.83 | 2021-2022 | |
| Pfizer INC. | $197.83 | 2021-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelina Dimatteo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.